Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

For Industry

Public Meeting on Lung Cancer Patient-Focused Drug Development

On June 28, 2013, FDA conducted a public meeting on Patient-Focused Drug Development for lung cancer. FDA is interested in obtaining patient input on the impact of lung cancer on daily life and the available therapies for lung cancer.

Date: June 28, 2013 
Time: 8:30 a.m. to 12:30 p.m 

FDA White Oak Campus
10903 New Hampshire Ave.
Building 31, Room 1503 B and C (Great Room)
Silver Spring, MD 20993  

(Information about arrival to FDA's White Oak campus)

Registration: To register for this meeting, visit
Registration closed on June 21, 2013.  

To submit comments to the docket, go to!docketDetail;D=FDA-2013-N-0596.

The comment period has been extended. Electronic and written comments may be submitted to the docket by August 28, 2013.

Please note: In the July 5, 2013 Federal Register, the reference number for the original June 5, 2013 Federal Register is incorrect. Please refer to Federal Register (78 FR 33851):

Webcast Recordings (archived)

Summary Report  


Page Last Updated: 04/19/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English